InMed Pharmaceuticals Inc.
$0.72
▲
1.15%
2026-04-21 07:31:01
www.inmedpharma.com
NCM: INM
Explore InMed Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.4 M
Current Price
$0.72
52W High / Low
$7.98 / $0.57
Stock P/E
—
Book Value
$3.42
Dividend Yield
—
ROCE
-57.63%
ROE
-97.2%
Face Value
—
EPS
$-2.88
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
13
Beta
0.52
Debt / Equity
5.55
Current Ratio
5.94
Quick Ratio
6.47
Forward P/E
-0.11
Price / Sales
0.53
Enterprise Value
$-4.38 M
EV / EBITDA
0.57
EV / Revenue
-0.97
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 2. | Evolus, Inc. | $5.08 | — | $330.5 M | — | -24.97% | 587.36% | $12.28 / $3.86 | $-0.35 |
| 3. | China Pharma Holdings, Inc. | $0.67 | — | $26.84 M | — | -46.43% | -20.91% | $2.6 / $0.5 | $1.47 |
| 4. | Akanda Corp. | $3.42 | — | $1.89 M | — | -102.48% | -60.86% | $209.03 / $2.29 | $22.67 |
| 5. | Perrigo Company plc | $12.04 | — | $1.66 B | 9.63% | 4.16% | -38.66% | $28.43 / $9.22 | $21.33 |
| 6. | Amphastar Pharmaceuticals, Inc. | $22.92 | 10.43 | $1.02 B | — | 9.54% | 12.9% | $31.26 / $17.03 | $17.28 |
| 7. | Organigram Global Inc. | $1.51 | 15.08 | $274.04 M | — | -3.51% | 4.64% | $3.09 / $1.37 | $1.97 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.82 M | 1.12 M | 1.3 M | 1.26 M | 1.11 M | — |
| Operating Profit | -2.12 M | -1.76 M | -1.84 M | -2.12 M | -2.21 M | — |
| Net Profit | -2.03 M | -1.73 M | -1.79 M | -2.12 M | -2.58 M | — |
| EPS in Rs | -0.61 | -0.52 | -0.54 | -0.64 | -0.78 | -2.71 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.94 M | 4.6 M | 4.14 M | 1.09 M |
| Operating Profit | -7.92 M | -8.13 M | -8.38 M | -13.79 M |
| Net Profit | -8.16 M | -7.68 M | -7.95 M | -18.6 M |
| EPS in Rs | -2.46 | -2.32 | -2.4 | -5.61 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 15.58 M | 11.82 M | 14.11 M | 12.79 M |
| Total Liabilities | 2.15 M | 2.62 M | 2.02 M | 3.71 M |
| Equity | 13.43 M | 9.21 M | 12.09 M | 9.08 M |
| Current Assets | 12.87 M | 8.69 M | 11.33 M | 9.6 M |
| Current Liabilities | 1.84 M | 1.97 M | 2 M | 3.32 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.77 M | -6.99 M | -7.28 M | -15.58 M |
| Investing CF | 0 M | -0.01 M | -0.66 M | -0.67 M |
| Financing CF | 12.27 M | 4.65 M | 10.68 M | 15.07 M |
| Free CF | -7.77 M | -7 M | -7.45 M | -15.62 M |
| Capex | — | -0.01 M | -0.16 M | -0.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 11.18% | 279.61% | — | — |
| Earnings Growth % | 3.42% | 57.27% | — | — |
| Profit Margin % | -166.94% | -192.18% | -1707.32% | — |
| Operating Margin % | -176.92% | -202.6% | -1265.95% | — |
| Gross Margin % | 23.94% | 33.93% | 49.89% | — |
| EBITDA Margin % | -153.64% | -188.19% | -1218.98% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-11-14 | 1:0.05 |
| 2022-09-07 | 1:0.04 |